Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:38 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1113
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 709–720 of 1,113 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

NCT04747912
Status at this site: Recruiting
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia
Interventions
Inotuzumab ozogamicin, Dasatinib, Dexamethasone, Methotrexate, Vincristine, Ponatinib, Purinethol (6-Mercaptopurine), Prednisone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
Site status not listed — check the official record
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 3 Interventional

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

NCT01953588
Site status not listed — check the official record
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
fulvestrant, anastrozole
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
856
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757
Site status not listed — check the official record
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 2 Interventional

MMRC Horizon One: RRMM (MMRC-099)

NCT06171685
Site status not listed — check the official record
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Teclistamab Monotherapy, Teclistamab
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry

NCT06030063
Status at this site: Recruiting
View directory record Official record
Conditions
Cesarean Delivery, General Anesthesia
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
15 Years to 55 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
34
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting No phase listed Observational

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

NCT03737695
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity Intervention for Black Women With Asthma

NCT05726487
Site status not listed — check the official record
View directory record Official record
Conditions
Asthma
Interventions
ACTION Intervention, Education Control
Behavioral · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 2 Interventional Results available

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

NCT03944941
Site status not listed — check the official record
View directory record Official record
Conditions
Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Interventions
Avelumab, Cetuximab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
428
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 274 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
Status at this site: Recruiting
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 1, 2026, 8:38 PM EST
Active, not recruiting Phase 3 Interventional

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778
Site status not listed — check the official record
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 1, 2026, 8:38 PM EST

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.